Corporate Corruption News StoriesExcerpts of Key Corporate Corruption News Stories in Major Media
Note: This comprehensive list of corporate corruption news stories is usually updated once a week. Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.
When nurse Meleney Gallagher was told to line up with her colleagues on the renal ward at Sunderland Royal Hospital, for her swine flu vaccination, she had no idea the injection she was about to have had not gone through the usual testing process. It had been rushed into circulation after the swine flu virus had swept across the globe in 2009. Gallagher was one of thousands of NHS staff vaccinated with Pandemrix, a vaccine made by pharmaceutical giant GlaxoSmithKline (GSK). Eight years later, her career in the NHS is a memory and she's living with incurable, debilitating narcolepsy and suffers from cataplexy, a sudden, uncontrollable loss of muscle tone that can cause her to collapse without warning. Because of her condition, she can no longer work or drive. People with narcolepsy experience chronic fatigue and difficulty sleeping at night. They can have night terrors, hallucinations, and a range of mental health problems. Gallagher is not alone. More than a dozen frontline NHS staff are among around 1,000 adults and children across Europe who are believed to have developed narcolepsy after being given Pandemrix. Gallagher and four other NHS professionals – two nurses, a community midwife, and a junior doctor – have told how they felt pressured into receiving the vaccine, were given misleading information, and ultimately lost their careers. They are all suing GlaxoSmithKline seeking compensation for what they believe was a faulty drug that has left them with lifelong consequences.
Note: Yet the media and big Pharma continually tout the safety of their vaccines. For more along these lines, see concise summaries of deeply revealing news articles on vaccines from reliable major media sources.
Ask people to name Pfizer's best-selling product and many would opt for one of its most famous drugs: Viagra, for erectile dysfunction, or Lipitor, to reduce high cholesterol. But they would all be wrong. The top-seller is not a drug but a vaccine: Prevnar, which prevents pneumonia, meningitis and other infections caused by pneumococcus bacteria. Prevnar generated revenues of $6.25bn last year – almost three times as much as Viagra. This was up 40 per cent from the year before, after the expert panel that advises on US vaccine policy recommended its use in over-65s as well as in children. Pfizer is one of just four pharma groups with large vaccines operations. The others are GlaxoSmithKline of the UK, Sanofi of France and Merck of the US. All four reported stronger sales growth in vaccines than in pharmaceuticals last year and operating margins were comparable with pharma at around 25-30 per cent. Pricing remains a sensitive topic, however, especially in the developing world. MĂ©decins Sans FrontiĂ¨res, the health charity, last month launched a challenge against Pfizer's patent on Prevnar in a bid to allow Indian companies to produce the vaccine cheaper. Manica Balasegaram, executive director of the MSF Access Campaign, says it could be produced in India for $6 per child, compared with Pfizer's reduced $10 price. Critics argue that consolidation in the industry has left too few companies, developing too few vaccines – and that those that do exist tend to be aimed at rich countries.
Note: Read this eye-opening article showing how powerful financial interests control the public narrative about vaccines. For more along these lines, see concise summaries of deeply revealing news articles on vaccines from reliable major media sources.
The announcement this week that a cheap, easy-to-make coronavirus vaccine appeared to be up to 90 percent effective was greeted with jubilation. But since unveiling the preliminary results, AstraZeneca has acknowledged a key mistake in the vaccine dosage received by some study participants, adding to questions about whether the vaccine's apparently spectacular efficacy will hold up under additional testing. Scientists and industry experts said the error and a series of other irregularities and omissions in the way AstraZeneca initially disclosed the data have eroded their confidence in the reliability of the results. The regimen that appeared to be 90 percent effective was based on participants receiving a half dose of the vaccine followed a month later by a full dose; the less effective version involved a pair of full doses. AstraZeneca disclosed in its initial announcement that fewer than 2,800 participants received the smaller dosing regimen, compared with nearly 8,900 participants who received two full doses. Moncef Slaoui, the head of Operation Warp Speed, the U.S. initiative to fast-track coronavirus vaccines, noted another limitation in AstraZeneca's data. On a call with reporters, he suggested that the participants who received the half-strength initial dose had been 55 years old or younger. The fact that the initial half-strength dose wasn't tested in older participants, who are especially vulnerable to Covid-19, could undermine AstraZeneca's case to regulators that the vaccine should be authorized for emergency use.
Note: Learn in this revealing article how vaccine trials are rigged. This article spells out how vaccine makers are above the law and face no consequences for damage from vaccines. For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and vaccines from reliable major media sources.
Purdue Pharma, the maker of OxyContin, pleaded guilty Tuesday to three federal criminal charges related to the company's role in creating the nation's opioid crisis. Purdue Pharma board chairman Steve Miller pleaded guilty on behalf of the company during a virtual federal court hearing in front of US District Judge Madeline Cox Arleo. The counts include one of dual-object conspiracy to defraud the United States and to violate the Food, Drug, and Cosmetic Act, and two counts of conspiracy to violate the Federal Anti-Kickback Statute. The plea deal announced in October includes the largest penalties ever levied against a pharmaceutical manufacturer, including a criminal fine of $3.544 billion and an additional $2 billion in criminal forfeiture, according to a Department of Justice press release. According to the US Centers for Disease Control and Prevention, about 70,000 Americans died of drug overdoses in 2018, just one year of the opioid crisis, and about 70% of those deaths were caused by prescription or illicit opioids like OxyContin. Several civil lawsuits against Purdue Pharma related to the opioid crisis are still ongoing as the company undergoes bankruptcy proceedings. The Plaintiffs' Executive Committee in the National Prescription Opiate Litigation Multi-District Litigation called Purdue Pharma's guilty plea "long overdue." "Their illegal and profit-seeking actions were egregious. It is important to note, however, that they are just one company in one part of the larger opioid supply chain," [the plaintiffs'] attorneys ... said.
Note: The company pays huge fines for the deaths of countless thousands, yet the CEO and others responsible face no legal charges. Where is the deterrent for this egregious behavior? For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.
People who work at the U.S. Food and Drug Administration (FDA) as medical reviewers are responsible for parsing the risks and benefits of a particular drug before it gets the agency's approval. But a new report from two researchers at the Oregon Health and Science University, published in the journal The BMJ, suggests many of these medical reviewers go on to work for the drug companies they oversaw while working for the government. The study's authors ... looked at the FDA's list of haematology-oncology drug approvals from 2006 to 2010 and scanned all medical reviews from 2001 to 2010 in the agency's database, then looked up the subsequent jobs of the people who worked as medical reviewers for those drug approvals. The researchers found that among 55 people who worked as haematology-oncology medical reviewers from 2001 to 2010, 27 continued in their roles at the FDA, two people worked at the FDA but held other appointments, and 15 left the FDA to work with or consult for the biopharmaceutical industry. "If you know in the back of your mind that a major career opportunity after the FDA is going to work on the other side of the table, I worry it can make you less likely to put your foot down," says study author Dr. Vinay Prasad. "Regulators may be less willing to be very tough, and I worry that is happening." Prasad says he would like to see more transparency from the FDA on the number of people who go from the agency to the drug industry.
The Trump administration this month announced that one of its largest pandemic-related contracts would go to a little-known biodefense company named Emergent BioSolutions. The $628 million deal to help manufacture an eventual vaccine cemented Emergent's status as the highest-paid and most important contractor to the HHS office responsible for preparing for public health threats and maintaining the government's stockpile of emergency medical supplies. Emergent has long been the government's sole provider of BioThrax, a vaccine for anthrax poisoning. Emergent's advocacy for biodefense spending over more than a decade was aided by influential allies in Washington and tens of millions of dollars in lobbying campaigns. "It has strategically placed itself to be, let's just say, the company that can't fail," said a former senior government official who worked with Emergent on stockpile operations. The company that would become Emergent began as BioPort Corp., formed in 1998 to buy an aging, state-owned company in Lansing, Mich., that was the only licensed supplier of anthrax vaccine to the Pentagon. The Pentagon ... awarded a $29 million no-bid contract for the anthrax vaccine, BioThrax. Controversy swamped the operation. Hundreds of U.S. troops who received the BioThrax treatment complained of bad reactions, such as headaches and nerve problems. Some troops risked courts-martial by refusing vaccination. Emergent spent nearly $4 million on lobbying last year alone.
Note: To understand the huge influence of lobbying and profits on the development and stockpiling of vaccines, don't miss reading this entire, eye-opening article. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption and vaccines from reliable major media sources.
The Food and Drug Administration is under pressure from the Trump administration to approve drugs faster, but researchers at the Yale School of Medicine found that nearly a third of those approved from 2001 through 2010 had major safety issues years after the medications were made widely available to patients. Seventy-one of the 222 drugs approved in the first decade of the millennium were withdrawn, required a "black box" warning on side effects or warranted a safety announcement about new risks, Dr. Joseph Ross ... and colleagues reported in JAMA. The Yale researchers' previous studies concluded that the FDA approves drugs faster than its counterpart agency in Europe does and that the majority of pivotal trials in drug approvals involved fewer than 1,000 patients and lasted six months or less. It took a median of 4.2 years after the drugs were approved for these safety concerns to come to light, the study found, and issues were more common among psychiatric drugs, biologic drugs, drugs that were granted "accelerated approval" and drugs that were approved near the regulatory deadline for approval. "All too often, patients and clinicians mistakenly view FDA approval as [an] indication that a product is fully safe and effective," [Dr. Caleb Alexander] says. "Nothing could be further from the truth. We learn tremendous amounts about a product only once it's on the market and only after use among a broad population."
The chairman and CEO of Pfizer, Albert Bourla, sold $5.6 million worth of stock in the pharmaceutical company on Monday. The sale took place on the same day Pfizer announced that its experimental coronavirus vaccine candidate was found to be more than 90% effective. Bourla's sale of Pfizer stock was part of a trading plan set months in advance. Known as 10b5-1 plans, they essentially put stock trades on autopilot. Executives are supposed to adopt these plans only when they are not in possession of inside information that can affect a company's stock price. On Aug. 19, Bourla implemented his stock-trading plan. The next day, Aug. 20, Pfizer issued a press release ... confirming that Pfizer and its German partner, BioNTech, were "on track to seek regulatory review" for its vaccine candidate. Daniel Taylor, an expert in insider trading ... told NPR that the close timing between the adoption of Bourla's stock plan and the press release looked "very suspicious." "It's wholly inappropriate for executives at pharmaceutical companies to be implementing or modifying 10b5-1 plans the business day before they announce data or results from drug trials," Taylor said. The stock sales by Pfizer's CEO brought to mind similar concerns with another coronavirus vaccine-maker, Moderna. Multiple executives at Moderna adopted or modified their stock-trading plans just before key announcements about the company's vaccine. Those executives have sold tens of millions of dollars in Moderna stock.
Moderna CEO StÄ‚©phane Bancel more than tripled the number of his company shares to be sold through an executive stock plan that was changed just days after the biotech in May announced positive early results for its coronavirus vaccine. Moderna's shares spiked on the May news, rising 30% in just one day. After seeking the executive stock plan change in May, Bancel sold more than 72,000 Moderna shares in the first 16 days of July, generating nearly $4.8 million for the executive. That was more than triple the 22,000 shares he had previously scheduled to sell during the same period through the company's executive trading plan. Another top Moderna executive, President Stephen Hoge, also had his pre-programmed executive trading plan reset around the same time. The change allowed him to sell $1.9 million worth of Moderna stock in the first two weeks of July. The executives' ... sales were made through what are known as 10b5-1 stock plans. These arrangements must be set up or amended at least 30 days before any transactions are executed; they are commonly used at publicly traded companies to help shield executives from potential claims of insider trading. The fact that the plans were changed during the pandemic as news was emerging about the company's closely watched coronavirus vaccine raises new questions about how Moderna executives have pocketed millions of dollars in recent months.
Eleven-year-old Allie sways back and forth. She rolls her eyes into her head and collapses onto the bed behind her. After lying there motionless for a moment, she pops back up. "Um, I wasn't really sure what else to add, 'cause all that was requested was to faint while putting my eyes backwards," she says to the camera, thanking a user who goes by "Martin" for the suggestion. Allie's channel is full of skits that she has eagerly filmed at the request of strangers on YouTube. She's learned that her audience particularly enjoys watching her pretend to pass out and hypnotize herself; those kinds of requests come in all the time. For Allie ... the attention is exciting. To the girl's great delight, her dizzy-themed videos randomly blow up sometimes, pulling in thousands of views despite her small following. She refers to her viewers as "fans" and promises to film whatever they'd like to see. That often means unwittingly acting out sexual fetishes for predators, who flock to her content like flies. This didn't happen by accident. YouTube's automated recommendation engine propels sexually implicit videos of children like Allie from obscurity into virality and onto the screens of pedophiles. Executives at the Google-owned company are well aware of this. Over the years, YouTube has claimed repeatedly that keeping children safe on its platform is a top priority. But ... the company has actually continued to amplify such videos into virality and to specifically steer them toward users seeking sexual content and footage of partially clothed kids.
The U.S. Department of Education says it is opening an investigation into Yale and Harvard universities for failing to disclose hundreds of millions of dollars in gifts and contracts from foreign donors. The two Ivy League schools have been singled out in a federal crackdown on institutions of higher learning for allegedly not reporting foreign donations of more than $250,000, as required by law under Section 117 of the Higher Education Act. The Department of Education said Yale failed to disclosed a total of $375 million in foreign money and that it was concerned that Harvard may not have fully complied with reporting requirements. The investigation of Yale and Harvard is part of a larger examination by the DOE, which says its enforcement efforts, since July, have triggered the reporting of approximately $6.5 billion in previously undisclosed foreign money, much of it from China, Saudi Arabia, Qatar and the United Arab Emirates, according to the department. In the case of Yale, the letter from the DOE specifically requested all records from the school related to gifts or contracts from Saudi Arabia, Saudi nationals, China, Huawei Technologies and ZTE. Huawei and ZTE ... were placed on a U.S. sanctions blacklist last year. In February of last year, a Senate report described China's influence on the U.S. education system as "effectively a black hole," because universities were failing to report foreign money.
Note: For more along these lines, see concise summaries of deeply revealing news articles on corporate corruption from reliable major media sources.
When Facebook and Twitter moved quickly this week to limit the spread of an unverified political story published by the conservative-leaning New York Post, it led to predictable cries of censorship from the right. But it also illustrated the slippery hold even the largest tech companies have on the flow of information. While Facebook and Twitter have often been slow to combat apparent misinformation ... their response in this case shows how quickly they can move when they want to. For the first time in recent memory, the two social media platforms enforced rules against misinformation on a story from a mainstream media publication. The story in question, which has not been confirmed by other publications, cited unverified emails from Democratic presidential nominee Joe Biden's son that were reportedly discovered by President Donald Trump's allies. Facebook used the possibility of false information as the reason to limit the article's reach, which means its algorithm shows it to fewer people, much the way you might not see as many posts from friends you don't interact with often. Twitter, meanwhile, blocked users from tweeting out the link to the story and from sending it in private messages. Though they acted quickly, both companies stumbled on communicating their decision to the public. In part because of this, and in part by the mere act of trying to limit the story, the tech platforms soon became the story.
Note: For more on this important story, read Matt Taibbi's article titled "With the Hunter Biden Expose, Suppression is a Bigger Scandal Than The Actual Story." For more along these lines, see concise summaries of deeply revealing news articles on media manipulation from reliable sources.
Purdue Pharma LP agreed to plead guilty to criminal charges over the handling of its addictive prescription opioid OxyContin, in a deal with U.S. prosecutors that effectively sidestepped paying billions of dollars in penalties and stopped short of criminally charging its executives or wealthy Sackler family owners. Prosecutors imposed significant penalties exceeding $8 billion against Purdue, though the lion's share will go largely unpaid. Purdue agreed to pay $225 million toward a $2 billion criminal forfeiture, with the Justice Department foregoing the rest if the company completes a bankruptcy reorganization dissolving itself and shifting assets to a "public benefit company," or similar entity, that steers the $1.775 billion unpaid portion to thousands of U.S. communities suing it over the opioid crisis. A $3.54 billion criminal fine and $2.8 billion civil penalty are likely to receive cents on the dollar as they compete with trillions of dollars of other claims from those communities and other creditors in Purdue's bankruptcy proceedings. Members of the billionaire Sackler family who own Purdue agreed to pay a separate $225 million civil penalty for allegedly causing false claims for OxyContin to be made to government healthcare programs such as Medicare, according to court records. Neither the Sacklers nor any Purdue executives were criminally charged. Purdue reaped more than $30 billion from sales of OxyContin over the years, enriching Sackler family members while funneling illegal kickbacks to doctors and pharmacies.
Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.
Evidence of what appears to be aggressive animal abuse, practices leading to heightened disease risk and cows being passed off as organic at a Texan auctioneers has been presented to the US Department of Agriculture (USDA) by undercover welfare investigators. The ... investigation centres on Texan auctioneers, Erath County Dairy Sales (ECDS). Undercover video footage filmed at ECDS between January and March 2020 ... was delivered to the USDA by the US-Brazil based NGO, Strategies for Ethical and Environmental Development (Seed). In one video, the undercover investigator, hired as an animal handler, is told that removing a cowĂ˘â‚Źâ„˘s ear tags, and replacing them with new Ă˘â‚ŹĹ’back tagsĂ˘â‚ŹĹĄ that indicate a cow is organic, can triple or quadruple their meat sale value. The investigator said he witnessed the tag switching process. First, a bladed tool was used to remove the ear tags, which are part of the USDAĂ˘â‚Źâ„˘s animal disease traceability framework. These tags were not replaced. Instead, another tag, known as a back tag or sticker, was glued to the cowĂ˘â‚Źâ„˘s back. The stickers indicate the cow is organic and from Texas. A lawyer for California-based NGO, Animal Legal Defense Fund, said she was Ă˘â‚ŹĹ’not too surprisedĂ˘â‚ŹĹĄ by the tag switching accusations. Ă˘â‚ŹĹ’We have seen this type of thing before,Ă˘â‚ŹĹĄ said Kelsey Eberly. She fears the practice is Ă˘â‚ŹĹ’more commonĂ˘â‚ŹĹĄ than people would expect, mainly Ă˘â‚ŹĹ’because the price premium is so much higherĂ˘â‚ŹĹĄ for organic and better welfare meat and dairy.
Note: For more along these lines, see concise summaries of deeply revealing news articles on food system corruption from reliable major media sources.
Animal agriculture industry groups defending factory farms engage in campaigns of surveillance, reputation destruction, and other forms of retaliation against industry critics and animal rights activists, documents obtained through a FOIA request from the U.S. Department of Agriculture reveal. That the USDA possesses these emails and other documents demonstrates the federal government’s knowledge of, if not participation in, these industry campaigns. These documents detail ongoing monitoring of the social media of news outlets, including The Intercept, which report critically on factory farms. They reveal private surveillance activities aimed at animal rights groups and their members. They include discussions of how to create a climate of intimidation for activists who work against industry abuses, including by photographing the activists and publishing the photos online. And they describe a coordinated ostracization campaign that specifically targets veterinarians who criticize industry practices. One of the industry groups central to these activities is the Animal Agriculture Alliance, which represents factory farms and other animal agriculture companies. The group boasts that one of its prime functions is “Monitoring Activism,” by which they mean: “We identify emerging threats and provide insightful resources on animal rights and other activist groups by attending their events, monitoring traditional and social media and engaging our national network.”
Note: Watch an interview with Dr. Crystal Heath, a veterinarian targeted by Animal Agricultural Alliance for her activism against inhumane factory farming practices. For more along these lines, see concise summaries of deeply revealing news articles on food system corruption from reliable major media sources.
The Trump administration has compared Operation Warp Speed's crash program to develop a COVID-19 vaccine to the Manhattan Project. And like the notoriously secretive government project to make the first atomic bomb, the details of Operation Warp Speed's work may take a long time to unravel. One reason is that Operation Warp Speed is issuing billions of dollars' worth of coronavirus vaccine contracts to companies through a nongovernment intermediary, bypassing the regulatory oversight and transparency of traditional federal contracting mechanisms, NPR has learned. Instead of entering into contracts directly with vaccine makers, more than $6 billion in Operation Warp Speed funding has been routed through a defense contract management firm called Advanced Technologies International, Inc. ATI then awarded contracts to companies working on COVID-19 vaccines. As a result, the contracts between the pharmaceutical companies and ATI may not be available through public records requests, and additional documents are exempt from public disclosure for five years. [Robin] Feldman, of UC Hastings, says the administration's comparison of Operation Warp Speed to the Manhattan Project is troubling. "I think that's completely the wrong image," she says. "The right analogy, I think, for Operation Warp Speed is the penicillin effort in World War II. We can do a lot of good together, but we have to make sure pharma companies aren't taking advantage of the crisis."
Note: Read an excellent article showing how most of these contracts are linked to the CIA and DHS and more. For more along these lines, see concise summaries of deeply revealing news articles on government corruption and the coronavirus from reliable major media sources.
Rep. Katie Porter (D-Calif.) got out her marker and scrawled a figure on the whiteboard beside her: $13 million. “Do you know what this number is?” she asked Mark Alles, the former CEO of the pharmaceutical company Celgene, as he testified remotely before the House Oversight Committee on Wednesday. “Does it ring any bells?” Alles could hardly get his answer out before Porter scribbled more math on the board. That multimillion figure — his total compensation in 2017 — was already 200 times the average income in the United States, the congresswoman pointed out. It got even larger, she said, after Celgene needlessly tripled the cost of a cancer medication, thus securing himself hefty bonuses in return. As of early Thursday, the rapid-fire interrogation had been viewed more than 15 million times on Twitter — the latest in a long list of her viral cross-examinations. These stunning exchanges at congressional hearings have themselves gained plenty of attention beyond Capitol Hill — especially when Porter pulls out what one person on Twitter dubbed “her mighty whiteboard of truth.” It is this kind of clear, insistent inquiry that has made Porter — a consumer protection lawyer ... who studied bankruptcy law under Sen. Elizabeth Warren (D-Mass.) — so effective at grilling everyone from Mark Zuckerberg to little-known Trump appointees, all with a dry-erase marker and some simple math. “No one has ever wielded a weapon as terrifying as Katie Porter’s whiteboard,” wrote Molly Wood, a public radio journalist.
Note: For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.
Facebook has suspended the accounts of several environmental organizations less than a week after launching an initiative it said would counter a tide of misinformation over climate science on the platform. Groups such as Greenpeace USA, Climate Hawks Vote and Rainforest Action Network were among those blocked from posting or sending messages on Facebook over the weekend. Activists say hundreds of other individual accounts linked to indigenous, climate and social justice groups were also suspended. The suspended people and groups were all involved in a Facebook event from May last year that targeted KKR & Co, a US investment firm that is backing the Coastal GasLink pipeline, a 670km-long gas development being built in northern British Columbia, Canada. The suspensions, the day before another online action aimed at KKR & Co, has enraged activists who oppose the pipeline for its climate impact and for cutting through the land of the Wetʼsuwetʼen, a First Nations people. “Videos of extreme violence, alt-right views and calls for violence by militias in Kenosha, Wisconsin, are allowed to persist on Facebook,” said Delee Nikal, a Wet’suwet’en community member. “Yet we are banned.” Many of the accounts have now been restored, but a handful are still blocked. The suspensions came just a few days after the social media giant said it was launching a “climate science information center” to counter ... posts that reject the established science of the climate crisis.
Netflix’s brilliant new 90-minute docu-drama, The Social Dilemma ... might be the most important watch of recent years. The film, which debuted at Sundance Film Festival in January, takes a premise that’s unlikely to set the world alight ... ie that Facebook, Twitter, Instagram et al aren’t exactly creating a utopia. Its masterstroke is in recruiting the very Silicon Valley insiders that built these platforms to explain their terrifying pitfalls – which they’ve realised belatedly. You don’t get a much clearer statement of social media’s dangers than an ex-Facebook executive’s claim that: “In the shortest time horizon I’m most worried about civil war.” The commonly held belief that social media companies sell users’ data is quickly cast aside – the data is actually used to create a sophisticated psychological profile of you. What they’re selling is their ability to manipulate you, or as one interviewee puts it: “It’s the gradual, slight, imperceptible change in your own behaviour and perception. It’s the only thing for them to make money from: changing what you do, how you think, who you are.” Despite it being public knowledge that Vote Leave and Trump’s 2016 election campaign harvested voters’ Facebook data on a gigantic scale, The Social Dilemma still manages to find fresh and vital tales of how these platforms destabilise modern politics. Russia’s Facebook hack to influence the 2016 US election? “The Russians didn’t hack Facebook. They used the tools that Facebook made for legitimate advertisers,” laments one of the company’s ex-investors.
Global banks faced a fresh scandal about dirty money on Monday as they sought to limit the fallout from a cache of leaked documents showing they transferred more than $2 trillion in suspect funds over nearly two decades. Britain-based HSBC Holdings Plc, Standard Chartered Plc and Barclays Plc, Germany's Deutsche Bank AG and Commerzbank AG, and U.S.-headquartered JPMorgan Chase & Co and Bank of New York Mellon Corp were among the lenders named in the report by the International Consortium of Investigative Journalists and based on leaked documents. The report was based on 2,100 leaked suspicious activity reports (SARs), covering transactions between 1999 and 2017, filed by banks and other financial firms with the U.S. Department of Treasury's Financial Crimes Enforcement Network (FinCEN). Banks are required to file an SAR whenever handling funds that cause grounds for suspicion of criminal activity. The reports revealed broader problems with the monitoring system at the heart of global policing of money laundering and other criminal activity. Investors worried about the potential fallout for global banks, many of which have faced hefty fines in the past for lapses in controls and spent billions of dollars to bolster compliance. "It confirms what we already knew: that there are huge amounts of SARs being filed with relatively low numbers of cases brought through to prosecution,” said Etelka Bogardi, a Hong Kong-based financial services partner at Norton Rose Fulbright. "It also brings out the point that managing financial crime risk goes beyond making SARs," Bogardi said.
Note: The original ICIJ report is titled “Global banks defy U.S. crackdowns by serving oligarchs, criminals and terrorists.” Compare with the title of the New York Times article on this, “Banks Suspected Illegal Activity, but Processed Big Transactions Anyway.” A search on this topic shows that headlines of almost all major media have watered this down, likely to not upset the big banks. For more along these lines, see concise summaries of deeply revealing news articles on financial industry corruption from reliable major media sources.
Important Note: Explore our full index to revealing excerpts of key major media news stories on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.